Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
Yazar
Salman, Emad
Owen, William C
Schaefer, Anne
Tebbi, Cameron K
Chantrain, Christophe F
Cohen, Debra E
Karakas, Zeynep
Piccone, Connie M
George, Alex
Fixler, Jason M
Singleton, Tammuella C
Moulton, Thomas
Quinn, Charles T
de Castro Lobo, Clarisse Lopes
Almomen, Abdulkareem M
Goyal-Khemka, Meenakshi
Maes, Philip
Emanuele, Marty
Gorney, Rebecca T
Padgett, Claire S
Parsley, Ed
Kronsberg, Shari S
Kato, Gregory J
Gladwin, Mark T
Casella, James F
Barton, Bruce A
Kanter, Julie
Black, L Vandy
Majumdar, Suvankar
Inati, Adlette
Wali, Yasser
Drachtman, Richard A
Abboud, Miguel R
Kilinc, Yurdanur
Fuh, Beng R
Al-Khabori, Murtadha K
Takemoto, Clifford M
Sarnaik, Sharada A
Shah, Nirmish
Morris, Claudia R
Keates-Baleeiro, Jennifer
Raj, Ashok
Alvarez, Ofelia A
Hsu, Lewis L
Thompson, Alexis A
Sisler, India Y
Pace, Betty S
Noronha, Suzie A
Lasky, Joseph L
de Julian, Elena Cela
Godder, Kamar
Thornburg, Courtney Dawn
Kamberos, Natalie L
Nuss, Rachelle
Marsh, Anne M
Üst veri
Tüm öğe kaydını gösterÖzet
Key PointsQuestionCan poloxamer 188, an agent that is reported to reduce blood viscosity and cell-cell interactions, effectively reduce the duration of vaso-occlusive episodes (painful crises) in hospitalized patients with sickle cell disease? FindingsIn this randomized clinical trial that included 388 children and adults with sickle cell disease, treatment with poloxamer 188 vs placebo resulted in mean time to last dose of parenteral opioids during vaso-occlusive episodes of 81.8 vs 77.8 hours, a difference that was not statistically significant. MeaningAmong patients with sickle cell disease, poloxamer 188 did not significantly shorten the duration of painful vaso-occlusive episodes.
Koleksiyonlar
- Makale [92796]